Article By:
ChinaBio® Today
Saturday, November 4, 2017 4:58 PM EDT
Xynomic Pharma, a US-Shanghai clinical-stage oncology drug developer, acquired exclusive global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim. Xynomic, hoping BI 882370 is a best-in-class drug, agreed to a $502 million package.